aTyr Pharma says DSMB recommends continuation of study without any modifications

aTyr Pharma announced that an independent data and safety monitoring board, or DSMB, recommended that the ongoing Phase 3 EFZO-FIT study of its lead therapeutic candidate, efzofitimod, in patients with pulmonary sarcoidosis could continue without any modifications after a second pre-planned, interim analysis. “This second DSMB review for EFZO-FIT builds upon the favorable safety profile seen with efzofitimod to date. We expect to conduct additional DSMB reviews as we progress throughout the study,” said Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer of aTyr. “Current standard of care for patients with pulmonary sarcoidosis includes oral corticosteroids, which can incur significant side effects and toxicity. Efzofitimod has the potential to be a safe, non-steroidal treatment option for these patients, which is greatly needed.”